A PFS benefit for the pola-R-CHP arm was also seen in patients older than 60 years of age, with IPI score 3-5, and those with activated B-cell (ABC) subtype DLBCL. This evidence concerns the gene POLA1 and diffuse large B-cell lymphoma.